<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300586</url>
  </required_header>
  <id_info>
    <org_study_id>2005.386</org_study_id>
    <nct_id>NCT00300586</nct_id>
  </id_info>
  <brief_title>IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer Not Progressing on First Line Cisplatin-gemcitabine Chemotherapy Maintenance Chemotherapy With Gemcitabine or Sequential Treatment With Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to improve the duration of control disease for PS 0-1 patients
      who are not progressing on first-line cisplatin-gemcitabine chemotherapy. Standard therapy is
      for these patients to stop first-line chemotherapy after 4 to 6 cycles and to begin a
      second-line chemotherapy when progression of disease is occurring. Two approaches will be
      experimented in this trial in attempt to prolong progression free survival :

        -  Maintenance chemotherapy with single-agent gemcitabine continued till disease
           progression or toxicity.

        -  Sequential treatment with erlotinib immediately given after the end of first-line
           chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival since randomization</measure>
    <time_frame>time until progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival,</measure>
    <time_frame>no time limit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity (NCIC-CTC 3.0),</measure>
    <time_frame>time until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (as assessed by LCSS).</measure>
    <time_frame>until progression</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">842</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A (supervision)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>medical supervision, second line chemotherapy if progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (gemcitabicine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C (Erlotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>observation</intervention_name>
    <description>observation, second line chemotherapy if progression</description>
    <arm_group_label>A (supervision)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1250 mg/m² D1, D8 q21 days</description>
    <arm_group_label>B (gemcitabicine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>150 mg daily</description>
    <arm_group_label>C (Erlotinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented NSCLC (tumor tissue samples will be provided to look for
             assessment of EGFR status with CISH, immunochemistry and mutations) : adenocarcinoma,
             squamous cell carcinoma, large cell carcinoma. A cytological documentation of NSCLC is
             accepted.

          -  Stage IV disease or metastatic relapse in not previously irradiated areas of a NSCLC
             previously treated with surgery or radiation therapy (with a histologically documented
             proof of relapse) or stage III B with documented pleural involvement.

          -  Measurable disease according to the RECIST criteria.

          -  Prior radiotherapy authorized except for irradiation concerning measurable disease.

          -  Age &gt;18 and &lt; 70 years.

          -  PS &lt; 2.

          -  Normal hepatic function : serum bilirubin &lt; 1.5 ULN, SGOT (ASAT) and SGPT (ALAT) &lt; 2,5
             ULN ; in presence of liver metastases, SGOT and SGPT must be &lt; 5 x ULN.

          -  Creatinine clearance &gt; 60 mL/min.

          -  Granulocyte count &gt; 1,5 giga/L, platelet count &gt; 100 giga/L.

          -  Life expectancy &gt; 12 weeks.

          -  Written (signed) informed consent for use of tumors samples.

          -  Written (signed) informed consent to participate in the sudy.

        Exclusion Criteria:

          -  Small cell lung cancer, bronchiolo-alveolar carcinoma, neuro-endocrine carcinoma.

          -  PS &gt; 1.

          -  Prior chemotherapy other than cisplatin-gemcitabine.

          -  Prior therapy with EGFR inhibitor (e.g. monoclonal antibody).

          -  No concomitant therapy with phenytoin, carbamazepine, rifampicine or phenobarbital.

          -  Concomitant radiotherapy except for localized bone irradiation.

          -  Symptomatic brain metastases.

          -  Superior vena cava syndrome.

          -  Any unstable systemic disease : significant cardiovascular disease including
             myocardial infarction within the previous year, active infection, significant hepatic
             or renal disease.

          -  Pre-existing interstitial lung disease.

          -  Any inflammatory changes of the surface of the eyes.

          -  Psychiatric disease with inability to understand the study or to comply with follow-up
             procedures.

          -  Grade &gt; or = 2 peripheral neuropathy.

          -  Any other malignancies within 5 years (except for treated carcinoma in situ of the
             cervix or basal cell skin cancer).

          -  Pregnant or lactating women ; patients with reproductive potential must use effective
             contraception.

          -  Inability to comply with follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Pérol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maurice PEROL</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <last_update_submitted>December 28, 2011</last_update_submitted>
  <last_update_submitted_qc>December 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer ;</keyword>
  <keyword>metastatic ;</keyword>
  <keyword>chemotherapy ;</keyword>
  <keyword>erlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

